Reproductive biotechnology company Memphasys (ASX: MEM) is confident its commercial operations across the Middle East and North Africa will continue to be unaffected, despite ongoing geopolitical instability in parts of the region.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Chair of the Australian-based company’s commercialisation committee, Marjan Mikel, said that in fact the company is now expanding its commercial footprint across additional countries in the region with its partner ITL.
A review of operations, distribution networks and customer engagement across its key markets has confirmed all commercial activities, logistics, and partner operations are continuing as normal, with no material disruptions identified.
“Our on-the-ground model is designed to build demand at the clinic level across multiple markets, and this update reinforces the resilience of that approach. We are seeing continued utilisation in established markets like Qatar, alongside new orders and advancing regulatory pathways in additional countries,” said Mr Mikel.
“Importantly, our exposure is diversified across the region, and our supply chain and distribution framework remain fully operational. This positions us well to continue executing our commercial rollout strategy, despite the current geopolitical backdrop.”
Memphasys remains confident in the continued rollout of its flagship Felix system across the MENA region and broader international markets.
“Importantly, current demand and order activity… remains consistent with the company’s expectations and ongoing commercial rollout,” Mr Mikel said.
“Operations in Qatar remain fully operational and unaffected, with Hamad Medical Corporation (HMC) continuing to utilise the Felix System as part of its routine assisted reproductive technology (ART) procedures.”
He told shareholders HMC continues to generate consistent cartridge usage, reinforcing the recurring revenue profile associated with Felix adoption.
“The continuation of clinical use and procurement activity highlights both the embedded nature of the technology within clinical workflows and the resilience of demand in the IVF sector,” he explained today.
“Memphasys maintains ongoing engagement with HMC and local stakeholders, with no interruption to operations, logistics or customer support.
“This ongoing utilisation provides a stable foundation of recurring demand within the region, supporting broader commercial expansion.”
Memphasys also continues to make progress in advancing regulatory approvals and commercial entry into two key strategic markets in Egypt and Turkey.
The Felix system is a patented bio separation technology that isolates the most viable sperm cells for human assisted reproduction.
MEM is steady at 0.5cps today.
Join the discussion: See what HotCopper users are saying about Memphasys Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.